Illinois Advocates Prepare to Introduce First Psychedelics Measure
Advocates in the state of Illinois plan to present the state’s first-ever psychedelics reform measure for approval. They have already begun educating the community on the benefits of these drugs and garnering public support.
The reform measure proposes a broader decriminalization framework for a range of psychedelic substances. If the advocates are successful, they will put the state on track to adopting a framework to support the use of entheogenic medicines.
The proposed measure, the Illinois Compassionate Use of Natural Plants and Fungi Act (ICUNPFA), calls for the decriminalization of the use, possession, growing, creation, production, analysis, gifting and distribution of natural fungi and plants, including DMT, ibogaine, psilocin, psilocybin and mescaline. The proposal is being drafted by Rep. La Shawn Ford, with the help Jean Lacy, founder of the Illinois Psychedelic Society.
This initiative will also establish a psilocybin advisory board in the state, which would advise the Illinois Public Health Department on the provision of psilocybin services. The board would also provide advice on the establishment of licensing categories for psilocybin service centers, testing facilities, manufacturers and facilitators.
Lacy explained that the society was also offering a framework for psychedelic drugs to be purchased from a service center and administered in a supervised setting, noting that it was common knowledge that individuals were using these drugs regardless, which was why it was important to regulate a safe product for individuals to consume.
Lacy, who is a grower of mushrooms and a yoga therapist, has also assisted in the construction of a ketamine infusion center in Chicago. Soon after this, she founded the Illinois Psychedelic Society. Lacy will be working with Vilmarie Narloch in this reform effort for psychedelics. Narloch is the founder of Sana Healing Collective, which is a not-for-profit organization that provides a range of psychedelic services.
Narloch, who is also a clinical psychologist, stated in an interview that the proposal had focused on accessibility and equity, noting that they had altered the measure to make it accessible to an ordinary individual in the state to be a licensed service provider or own a service center in Illinois. She further explained that while the measure wouldn’t decriminalize all drugs, it did empower the state’s psilocybin advisory board to review drugs and give recommendations on whether to reschedule or decriminalize the drugs.
The proposal would also ensure equal access and protection for people of color who have been disproportionately impacted by the war on drugs. It would do so by ensuring that there were business owners of color who could best address the needs of individuals of color.
As advocates push for reform at the policy level, research and development teams at various companies such as Silo Pharma Inc. (OTCQB: SILO) are working to develop medicines from psychedelics and see them through the regulatory process before the public can access those treatments.
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at https://ibn.fm/SILO
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Advocates in the state of Illinois plan to present the state’s first-ever psychedelics reform measure for approval. They have already begun educating the community on the benefits of these drugs and garnering public support.
The reform measure proposes a broader decriminalization framework for a range of psychedelic substances. If the advocates are successful, they will put the state on track to adopting a framework to support the use of entheogenic medicines.
The proposed measure, the Illinois Compassionate Use of Natural Plants and Fungi Act (ICUNPFA), calls for the decriminalization of the use, possession, growing, creation, production, analysis, gifting and distribution of natural fungi and plants, including DMT, ibogaine, psilocin, psilocybin and mescaline. The proposal is being drafted by Rep. La Shawn Ford, with the help Jean Lacy, founder of the Illinois Psychedelic Society.
This initiative will also establish a psilocybin advisory board in the state, which would advise the Illinois Public Health Department on the provision of psilocybin services. The board would also provide advice on the establishment of licensing categories for psilocybin service centers, testing facilities, manufacturers and facilitators.
Lacy explained that the society was also offering a framework for psychedelic drugs to be purchased from a service center and administered in a supervised setting, noting that it was common knowledge that individuals were using these drugs regardless, which was why it was important to regulate a safe product for individuals to consume.
Lacy, who is a grower of mushrooms and a yoga therapist, has also assisted in the construction of a ketamine infusion center in Chicago. Soon after this, she founded the Illinois Psychedelic Society. Lacy will be working with Vilmarie Narloch in this reform effort for psychedelics. Narloch is the founder of Sana Healing Collective, which is a not-for-profit organization that provides a range of psychedelic services.
Narloch, who is also a clinical psychologist, stated in an interview that the proposal had focused on accessibility and equity, noting that they had altered the measure to make it accessible to an ordinary individual in the state to be a licensed service provider or own a service center in Illinois. She further explained that while the measure wouldn’t decriminalize all drugs, it did empower the state’s psilocybin advisory board to review drugs and give recommendations on whether to reschedule or decriminalize the drugs.
The proposal would also ensure equal access and protection for people of color who have been disproportionately impacted by the war on drugs. It would do so by ensuring that there were business owners of color who could best address the needs of individuals of color.
As advocates push for reform at the policy level, research and development teams at various companies such as Silo Pharma Inc. (OTCQB: SILO) are working to develop medicines from psychedelics and see them through the regulatory process before the public can access those treatments.
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at https://ibn.fm/SILO
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
